The Hematology Journal

Login   |   Register

Open Journal Systems


ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients

Amel Mebazaa, Alain Dupuy, Michel Rybojad, Frédéric Mouly, Isabelle Moulonguet, Marie-Dominique Vignon-Pennamen, Jacqueline Rivet, Anne Janin, Celeste Lebbé, Louis Dubertret, Patrice Morel, Hervé Bachelez, Pauline Brice


Systemic multiagent hemotherapy has been used to treat aggressive forms of primary cutaneous T-cell lymphomas (CTCL) with controversial results. Our objective was to retrospectively assess efficacy and toxicity of ESHAP (etoposide, cisplatin, high-dose aracytine, methylprednisolone) in patients with advanced CTCL. A total of 11 patients with aggressive primary CTCL, treated with the ESHAP protocol between 1995 and 2002, were studied. Two patients achieved complete remissions lasting 30þ and 6þ months, seven had partial remissions of short duration, one had stable disease and one experienced disease progression. ESHAP was poorly tolerated because of prolonged myelosuppression (91%) and infectious complications (82%). Our results suggest that ESHAP has a poor risk/benefit ratio in advanced CTCL because of the low number of complete remissions, the short duration of partial remissions and its high-grade toxicity.


cutaneous T-cell lymphomas; chemotherapy; survival

Full Text:


Submitted: 2013-08-29 09:42:05
Search for citations in Google Scholar
Related articles: Google Scholar


  • There are currently no refbacks.


The Hematology Journal was merged with Haematologica in 2005.



© PAGEPress 2008-2013     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185